Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease

Tools

Item Type:	Article
Title:	Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease
Creators Name:	Lotan, I., Chen, J.J., Hacohen, Y., Abdel-Mannan, O., Mariotto, S., Huda, S., Gibbons, E., Wilf-Yarkoni, A., Hellmann, M.A., Stiebel-Kalish, H., Pittock, S.J., Flanagan, E.P., Molazadeh, N., Anderson, M., Salky, R., Romanow, G., Schindler, P., Duchow, A.S., Paul, F. and Levy, M.
Abstract:	BACKGROUND: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown. OBJECTIVE: The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks. METHODS: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment. RESULTS: Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5-74 years), and the median disease duration was 4 months (range 0-93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral n = 14, bilateral n = 5, associated with transverse myelitis (TM), n = 1), followed by acute disseminated encephalomyelitis (ADEM) (n = 8), multifocal (n = 7), TM (n = 3), brainstem (n = 1), and other encephalitis (n = 1). A significant improvement in both the EDSS and VA measures was observed at follow-up compared to the time of IVIG treatment initiation (p < 0.0001 for both outcome measures). CONCLUSION: IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results.
Keywords:	MOGAD, IVIG, Acute Treatment, Outcomes, Effectiveness, Safety
Source:	Multiple Sclerosis Journal
ISSN:	1352-4585
Publisher:	Sage Publications
Volume:	29
Number:	9
Page Range:	1080-1089
Date:	August 2023
Additional Information:	Copyright © The Author(s), 2023.
Official Publication:	https://doi.org/10.1177/13524585231184738
External Fulltext:	View full text on external repository or document server
PubMed:	View item in PubMed

Repository Staff Only: item control page